MARKET

BCDA

BCDA

Biocardia Inc
NASDAQ
0.8597
-0.0603
-6.55%
After Hours: 0.8490 -0.0107 -1.24% 19:57 06/09 EDT
OPEN
0.8388
PREV CLOSE
0.9200
HIGH
0.9241
LOW
0.8311
VOLUME
2.25M
TURNOVER
--
52 WEEK HIGH
2.450
52 WEEK LOW
0.8311
MARKET CAP
9.78M
P/E (TTM)
-0.8299
1D
5D
1M
3M
1Y
5Y
1D
BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250
PUBT · 8h ago
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Lyell Immunopharma (LYEL) and BioCardia (BCDA)
TipRanks · 19h ago
BioCardia Raises $4.4 Million to Extend Cash Runway
TipRanks · 1d ago
BIOCARDIA ANNOUNCES $4.4 MILLION FINANCING
Reuters · 1d ago
BIOCARDIA - NET PROCEEDS EXPECTED TO EXTEND CASH RUNWAY INTO Q1 2027
Reuters · 1d ago
Weekly Report: what happened at BCDA last week (0601-0605)?
Weekly Report · 1d ago
BioCardia Announces $4.4 Million Financing
Barchart · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
Reuters · 4d ago
More
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Webull offers BioCardia Inc stock information, including NASDAQ: BCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCDA stock methods without spending real money on the virtual paper trading platform.